subjects sufficient to produce statistically significant differences for specific end points. Most of the trials achieved a statistically significant decrease in stroke incidence and deaths from strokes in the treated compared to the nontreated or the vigorously treated compared to the less vigorously treated subjects. One of the trials, however, the European Working Party on Hypertension in the Elderly (EWPHE), 7 barely failed to demonstrate a statistically significant decrease in stroke death rates, presumably because of the small number of events, despite noting a 32% decrease in stroke deaths in the treated compared to the placebo group. Because this finding is at variance with results of the other trials, we tend to accept the 32% reduction as significant. In interpreting some of the other studies, however, statistical validity has been abandoned and conclusions have been drawn by interpreters of the studies that may not be consistent with the available data. The Oslo Study, which is reported to demonstrate an increase in coronary heart disease mortality in the treated group, is an example of this. The numbers of events at 5 years in the Oslo Study are small (six coronary deaths occurring in the treated group versus two in the untreated group). These differences were not statistically significant, and the authors cautioned that "valid conclusions regarding the impact of antihypertensive treatment on mortality should not be drawn." 3 In the 10-year Oslo data, 4 14 coronary deaths were recorded in the treated versus only three in the CLINICAL TRIALS AND MANAGEMENT OF HYPERTENSION/Moser m-81 untreated subjects. While these numbers did achieve statistical significance, the authors suggested caution in their interpretation -for an excellent reason: none of the original patients in the 5-year study were actually followed from the fifth to the tenth year. Half or even more of the treated patients might have been taken off medication because their blood pressures were controlled or, on the other hand, an unknown number of the control group might have been placed on medication because their blood pressures were too high. The deaths recorded were those from a death registry. No information on blood pressure levels, treatment, or morbidity is available. These types of data should not be used to establish whether or not therapy was beneficial.
Subset analyses or post hoc reviews of data have also been used in the interpretation of several of the clinical trials, especially the Multiple Risk Factor Intervention Trial (MRFTT).
8 These analyses often suggest conclusions for data that may have occurred by chance. For example, we have analyzed results of the MRFTT study 9 and suggested that the poor outcome reported in the subgroup of patients in the special intervention (SI) group with abnormal pretreatment electrocardiograms (ECGs) may be artifactual; a comparable usual care (UC) group experienced an unusually low coronary heart disease mortality. Certainly the explanation of hypokalemia resulting in severe arrhythmias and sudden death cannot be accepted without question when patients on either low or high dose chlorthalidone (with a greater degree of hypokalemia) had a lower death rate than patients on hydrochlorothiazide. Patients in the SI group with abnormal ECGs receiving chlorthalidone, either < 5 0 or > 5 0 mg/day, had a mortality rate of 4.84 and 1.84/1000 patient-years, respectively, compared to a rate of 7.20 and 8.01 /1000 patient-years in patients receiving either < 50 or > 50 mg/day of hydrochlorothiazide.
Although it is reasonable to look at clinical trials for clues or ideas for further investigations, it may be a mistake to generate hypotheses based on findings in a subset analysis that appear discordant with expected results of the trial. If a hypothesis cannot be proven, it is then especially important not to perpetrate it or use it to make clinical decisions, as I believe has been done with the MRFTT data.
In the original Veterans Administration (VA) study 10 of men who received treatment for moderately severe hypertension and in the U.S. Public Health Service (USPHS) study" of patients with less severe hypertension, findings included 1) decreased incidence of cerebrovascular events, 2) decreased progression to accelerated hypertension, and 3) decreased left ventricular failure. Although reversal of left ventricular hypertrophy was frequently observed, a statistically significant reduction of either myocardial infarction or sudden death was not observed.
Given the small number of relatively young patients in the USPHS study, it was not unexpected that atherosclerotic complications were not frequently or significantly reduced; atherosclerotic complications are usually not noted in hypertensive patients before the age of 50 to 55 years or until hypertension has persisted for many years. None of the treated patients, compared to 24 of 196 patients in the placebo group, progressed to more severe hypertension.
As Dr. Frohlich has noted in the preceding article of this issue, 12 the HDFP demonstrated not only a decrease in deaths from cerebrovascular accidents, but also in deaths from myocardial infarction in the group of patients treated vigorously (SC group) compared to the group of patients treated in the community (RC group). Blood pressures decreased from 153/96 to 129/83 mm Hg in the SC group, compared to a decrease from 153/96 to 141/88 mm Hg in the RC group. Critics of the HDFP note that blood pressure lowering may not have been the only reason for a decrease in mortality, since both cardiovascular and noncardiovascular mortality were reduced in the SC group. Could the reduced mortality rate have resulted from better overall medical care? This is possible, but it appears that the blood pressure differences accounted for the UI-82 differences in outcome: systolic and diastolic blood pressures were consistently higher in both the RC and SC patients who subsequently died than in survivors, regardless of the type of care they received. In addition, there were no significant differences in cholesterol levels, weight changes, or smoking habits in the two groups to account for the difference in overall mortality. The reversal of left ventricular hypertrophy and reduction in strokes and stroke deaths in a higher percentage of SC than RC patients also are difficult to ascribe to better general medical care.
It is important to note that vigorous (as compared to less intensive) treatment proved beneficial even after the onset of target-organ involvement (reduction of 22% in 5-year mortality in the subjects with pretreatment diastolic blood pressures [DBPs] of 90-104 mm Hg; Table 2 ). Yet the death rates were almost four times greater in patients with pretreatment target-organ damage than in patients with mild hypertension without detectable target-organ damage -a strong argument for early treatment.
The European Working Party Study on
Hypertension in the Elderly In the EWPHE trial, 840 subjects (average age 70-71 years) with average entry blood pressures of 182 to 183/101 mm Hg were randomly assigned to a treatment or placebo group. The administration of 25 mg of hydrochlorothiazide and 50 mg of triamterene was sufficient to lower blood pressure to goal levels in 51% of the treated group: 45% required two or more capsules, and only 35% required the addition of methyldopa. Serum potassium decreased by only 0.1 to 0.2 mEq/L, presumably because of the use of a potassiumsparing agent, and side effects were generally not significant.
Blood pressures were reduced by -10/ -6 mm Hg in the placebo group and by -32/ -13 mm Hg in the treated group at the end of the first year, with only a slight additional decrease in blood pressure in the treated group over the next 4 to 5 years. In an intention-totreat analysis, a decrease of 27% in total cardiovascular mortality, 38% in cardiac mortality, and 32% in deaths from cerebrovascular disease was noted in the treated compared to placebo patients. Benefit was noted in patients with DBPs of 90 to 99 mm Hg (de- These data appear to confirm previous impressions that therapy of elderly patients with both systolic and diastolic hypertension is beneficial, that blood pressure can be lowered, and that morbidity and mortality can be reduced. They are consistent with the findings of the 60-to-69-year-old cohort in the HDFP study and with the VA and Australian studies, where a 59 and 39% reduction in cardiovascular events occurred in treated subjects over 60 years of age. Extrapolation of the results of the EWPHE trial to general practice must be done with care, since the patients in this study were carefully selected and highly motivated.
The International Prospective Primary Prevention
Study in Hypertension The International Prospective Primary Prevention Study in Hypertension (IPPPSH) 13 was a complicated multination trial involving over 6000 patients. One group of 3172 patients was treated with a placebo or a diuretic plus any other drugs (except /3-blockers) that were necessary to lower blood pressure to goal level. Another group of 3185 patients received /3-blocker therapy plus any other drugs, including diuretics, that were necessary to lower blood pressure. The expected overall cardiovascular mortality was reduced in both groups to an equal degree but to the greatest degree in subjects with the lowest blood pressure. The authors concluded that it is the lowering of blood pressure and not the specific type of medication that reduces mortality and morbidity, and that the use of /3-adrenergic inhibitors in addition to other drugs did not appear to offer any great advantages over the use of diuretics plus drugs other than /3-blockers, except in nonsmoking males. Although there are problems with the design of this trial, the conclusions are of interest.
The Medical Research Council Trial
The MRC trial 1 of subjects with mild to moderate hypertension studied the efficacy of /3-adrenergic inhibitors and diuretics compared to placebos. This study included more than 17,000 patients with an age range of 35 to 64 years. Results included a significant reduction in the incidence of strokes and total cardiovascular events among patients receiving active antihypertensive therapy compared to those receiving the placebo, but the effect of therapy on fatal coronary events was minimal. The reduction in the incidence of strokes was noted in both smoking and nonsmoking patients in the diuretic-treated group, but only in nonsmokers treated with /3-blockers. On the other hand, nonsmoking patients in the /3-blocker-treated group were the only ones to achieve a small but definite reduction in coronary event rates. This finding was disappointing but not unexpected in this relatively short-term trial involving a population of individuals suifering from only mild hypertension with no other CLINICAL TRIALS AND MANAGEMENT OF HYPERTENSION/Afoser IU-83 measurable pretreatment cardiovascular disease. This finding was also in contrast to the data reported by the HDFP and EWPHE studies (Table 3) .
Two other important findings emerged from the MRC trial. First, 18% of the patients who had been randomly assigned to placebo or active therapy groups experienced a decrease in blood pressure to normotensive levels (usually within 3 months); this decrease was maintained throughout the course of the trial. This finding suggests that a period of observation is reasonable and that patients with less severe hypertension should be observed for a minimum of 3 to 6 months prior to being placed on specific antihypertensive medication.
14 The second finding of importance in the MRC trial was that 1011 or about one-eighth of all patients in the placebo group progressed to severe hypertension (blood pressures above 200/110 mm Hg) compared to only 76 patients in the actively treated group, a finding consistent with other studies and an argument for careful follow-up and early treatment of mild hypertension (Table 4 ). As noted in Table 4 , over 1300 subjects in the placebo or nontreated groups in the major clinical trials progressed to severe hypertension compared to only 82 of 11,206 subjects in the actively treated groups. No association between diuretic use and increased coronary death was established in the MRC trial. 
Results of Treatment for Mild Hypertension
The results of the MRC and the EWPHE studies (although these studies differed in design) are reasonably consistent with results of previous studies such as the HDFP and the ANBPS. That is, they offer further evidence that specific therapy and lowering of blood pressure in patients with mild hypertension, even in the elderly, is justified. However, these new studies were not designed to answer (and have not answered) questions regarding therapy for the patient with pretreatment DBP of 90 to 95 mm Hg.
Some have argued that the results of the clinical trials indicate that many patients may have to be treated to benefit a few and that, other than the HDFP (which was the only trial actually to test the hypothesis), there are still no data to support the treatment of the asymptomatic young patient with persistent DBPs between 90 and 95 mm Hg and no other risk factors. It is of interest, therefore, to apply the results of the trials summarized here to mildly hypertensive subjects (DBP 90-104 mm Hg) or to hypertensive subjects 60 years of age or over in the United States to estimate the possible overall benefits of therapy in these populations. It is important to recognize, however, that trial subjects may be different from those treated in clinical practice and that these are only estimates.
A cardiovascular event rate reduction in the MRC trial of 1.6/1000 patient-years and a reduction in stroke events of 1.2/1000 patient-years suggests a relatively minimal benefit but actually translates to 32,000 and 24,000 fewer events per year, respectively, in a population of approximately 20 million persons with mild hypertension in the United States (Table 5 ). The EWPHE reported a reduction of 13/1000 patient-years in cardiovascular deaths, which can be extrapolated to a potential 260,000 lives saved per year in the population of approximately 15 to 20 million elderly hypertensive patients in the United States. A 2.3/1000 patient-year reduction in death rate was noted in the HDFP (equivalent to 46,000 persons per year). 13 This is probably an underestimate -results might actually have been better if there had been a placebo group. If we extrapolate the HDFP data at 5 years (4.35 fewer total cardiovascular end points per 100 subjects between SC and RC patients) and assume that this benefit might continue at the same level for 15 years, with 13 fewer incidents per 100 effectively treated individuals with mild hypertension, it is possible that as many as 2,600,000 cardiovascular events could be prevented over this period of time.
Finally, in the placebo-controlled ANBPS, there was a decrease of 2/1000 in total fatal and 7.3/1000 patient-years in fatal and nonfatal end points in treated patients. This translates to a potential decrease in deaths of 40,000/year and in events of 146,000 in the 20 million mildly hypertensive patients in the United States.
As noted by Langford, 16 the benefits achieved in the ANBPS might have been greater if the placebo control group had proved more typical of the Australian population in general. As it evolved, the placebo group had approximately one third the death rate of an age-sex matched subset of the Australian population. The benefits of treatment in this trial were, therefore, probably understated. If we follow the argument of some investigators' 7 that 1721 patients would have to be treated for an additional 4 years just to prevent or postpone 10 deaths and 20 nonfatal morbid events (based upon the ANBPS), then treatment of mild hypertension could prevent 116,000 deaths and 232,000 morbid events in the United States alone. Finally, if these benefits were merely constant over 20 years with no further improvement in outcome (which might actually occur as a result of continuing effective treatment), the minimum benefit would be to postpone death for one person out of 25 (affecting 800,000 people) and to postpone or prevent any significant morbid events in one person out of seven (affecting 2,850,000 people; see Table 5 ). These are impressive numbers. The potential reduction in mortality alone would appear to make treatment of mild hypertension worthwhile, regardless of the reduction in morbidity or the possibility of preventing progression to severe hypertension or delaying the undetectable vascular changes that can occur in untreated hypertensive patients.
Despite the potential for benefit suggested by study findings, it is important to emphasize that at present it is impossible to preselect for treatment those individuals who are candidates for more severe hypertension or cardiovascular complications. If we follow the recommendations of the 1984 JNC report, 14 some patients will be treated pharmacologically who might not have progressed to more severe hypertension for many years -at a cost and with some potential for adverse reactions. These numbers can be reduced by careful follow-up of patients with mild hypertension over 3 to 4 months and the use of nonpharmacological therapy first. If subsequent pharmacological therapy is kept simple and relatively inexpensive, and attention is paid to minimizing side effects, die risk and inconvenience of treatment can be reduced and the benefit-risk ratio kept at a high level for the great majority of patients.
